Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

31.91
+1.695.58%
Volume:402.25K
Turnover:12.58M
Market Cap:5.09B
PE:11.49
High:31.96
Open:30.53
Low:30.53
Close:30.22
52wk High:46.48
52wk Low:25.28
Shares:159.69M
Float Shares:148.00M
Volume Ratio:0.73
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.77
ROE:102.75%
ROA:9.39%
PB:7.86
PE(LYR):11.52

Loading ...

TG Therapeutics Q4 2025 EPS $0.14 Misses $0.33 Estimate, Sales $192.574M Beat $192.213M Estimate

Benzinga
·
Feb 26

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises Briumvi Revenue Guidance

THOMSON REUTERS
·
Feb 26

TG Therapeutics Inc. Updates Financial Calendar

Reuters
·
Feb 23

Assessing TG Therapeutics (TGTX) Valuation After Long Term BRIUMVI Multiple Sclerosis Data Release

Simply Wall St.
·
Feb 20

TG Therapeutics Reports Five-Year BRIUMVI Data Showing Sustained Efficacy in Relapsing MS

Reuters
·
Feb 17

Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

GlobeNewswire
·
Feb 17

TG Therapeutics Partners with Christina Applegate to Launch Multiple Sclerosis Awareness Campaign

Reuters
·
Feb 09

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

Reuters
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

Reuters
·
Feb 06

BUZZ-TG Therapeutics rises on new data for autoimmune therapy

Reuters
·
Feb 06

TG Therapeutics startet Phase-3-Studie zu Ublituximab bei Kindern und Jugendlichen mit Multipler Sklerose

Reuters
·
Feb 06

TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum

Reuters
·
Feb 06

TG Therapeutics Announces Presentation of Data for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
Feb 06

TG Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Feb 03

TG Therapeutics Unveils New BRIUMVI Data in Multiple Sclerosis at ACTRIMS 2026

Reuters
·
Jan 28

TG Therapeutics Announces Schedule of Data Presentations for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
Jan 27

Stock Track | TG Therapeutics Soars 5.01% Intraday on High Growth Projections and Upside Potential

Stock Track
·
Jan 16

These under-the-radar stocks combine fast growth with big upside potential

Dow Jones
·
Jan 15

TG Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Jan 15

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

TIPRANKS
·
Jan 15